Cboe BZX · HELX
Franklin Genomic Advancements ETF financials
$44.40+0.23%
Close Sep 28, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q4 '19 Dec 31 | Q3 '19 Sep 30 | Q2 '19 Jun 30 | Q1 '19 Mar 31 | Q4 '18 Dec 31 | Q3 '18 Sep 30 | Q2 '18 Jun 30 | Q1 '18 Mar 31 | Q4 '17 Dec 31 | Q3 '17 Sep 30 | Q2 '17 Jun 30 | Q1 '17 Mar 31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $170.7M | $212.6M | $201.7M | $166.8M | $158.4M | $212.6M | $204.6M | $164.3M | $163.3M | $163.3M | $150.3M | $104.5M |
| Gross profit | $26.6M | $55.1M | $39.9M | $16.3M | $13.8M | $52.0M | $42.9M | $13.0M | $23.5M | $21.1M | $18.4M | -$825.0K |
| Gross margin | 15.6% | 25.9% | 19.8% | 9.7% | 8.7% | 24.5% | 21.0% | 7.9% | 14.4% | 12.9% | 12.2% | −0.8% |
| Operating income | $5.7M | $39.0M | $23.1M | $269.0K | -$3.5M | $31.2M | $24.8M | -$1.1M | $6.8M | $4.8M | $5.0M | -$17.7M |
| Net income | $7.9M | $31.4M | $16.7M | $1.3M | -$13.7M | $27.1M | $17.8M | -$2.6M | $50.6M | $2.3M | -$6.4M | -$16.4M |
| Net margin | 4.6% | 14.8% | 8.3% | 0.8% | −8.7% | 12.8% | 8.7% | −1.6% | 31.0% | 1.4% | −4.3% | −15.7% |
| Diluted EPS | $0.05 | $0.21 | $0.11 | $0.01 | $-0.10 | $0.18 | $0.12 | $-0.02 | $0.34 | $0.02 | $-0.04 | $-0.11 |
| EBITDA | $5.7M | $66.9M | $51.1M | $28.8M | -$3.5M | $58.9M | $52.6M | $26.7M | $6.8M | $31.1M | $30.6M | $13.2M |
| Operating cash flow | $79.8M | $57.3M | $66.8M | -$34.2M | $45.9M | $63.2M | $46.6M | $41.0M | $20.3M | $15.7M | -$13.2M | $28.8M |
| Free cash flow | -$15.4M | $39.1M | $51.0M | -$45.9M | -$35.7M | $49.7M | $25.9M | $19.8M | -$79.4M | -$21.3M | -$59.6M | -$19.2M |
| Diluted shares | 149.6M | 148.4M | 148.1M | 147.8M | 146.8M | 147.0M | 146.7M | 146.7M | 145.3M | 146.0M | 145.9M | 143.2M |
Balance sheet
| Period end | Dec 31 | Sep 30 | Jun 30 | Mar 31 | Dec 31 | Sep 30 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $208.4M | $286.3M | $261.1M | $220.0M | $279.5M | $325.1M |
| Short-term investments | — | — | — | — | — | — |
| Total debt | $405.9M | $413.4M | $424.5M | $429.2M | $440.3M | $448.0M |
| Total assets | $2.60B | $2.61B | $2.62B | $2.61B | $2.35B | $2.38B |
| Total liabilities | $893.7M | $931.2M | $968.4M | $977.5M | $730.0M | $746.3M |
| Shareholders' equity | $1.70B | $1.68B | $1.65B | $1.63B | $1.62B | $1.63B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology